Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Thumbnail Image
View / Download476.52 KB

Date

2017-02-03

Authors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

91
views
35
downloads

Citation Stats

Attention Stats

Abstract

Type

Journal article

Department

Description

Provenance

Subjects

Humans, Myelodysplastic Syndromes, Cyclopentanes, Pyrimidines, Enzyme Inhibitors, Maximum Tolerated Dose, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Leukemia, Myeloid, Acute, Young Adult, NEDD8 Protein

Citation

Permalink

https://hdl.handle.net/10161/19549

Published Version (Please cite this version)

10.1038/bcj.2017.1

Publication Info

Swords, RT, J Watts, HP Erba, JK Altman, M Maris, F Anwer, Z Hua, H Stein, et al. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood cancer journal, 7(2). p. e520. 10.1038/bcj.2017.1 Retrieved from https://hdl.handle.net/10161/19549.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles
Full item page

Scholars@Duke

Erba

Harry Paul Erba

Professor of Medicine

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.  

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.